Share This Article:

Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial

Full-Text HTML Download Download as PDF (Size:1347KB) PP. 83-98
DOI: 10.4236/aad.2013.23012    3,238 Downloads   6,013 Views   Citations

ABSTRACT

Background: 5-HT4receptors in cortex and hippocampus area are considered as a possible target for modulation of cognitive functions in Alzheimer’s disease (AD). A systems pharmacology approach was adopted to evaluate the potential of the 5-HT4 modulation in providing beneficialeffects on cognition in AD. Methods: A serotonergic synaptic cleft model was developed by integrating serotonin firing, release, synaptic half-life, drug/tracer properties (affinity and agonism) as inputs and5-HT4 activity as output. The serotonergic model was calibrated using bothinvivo data on free 5-HT levels in preclinical models and human imaging data. The model was further expanded to other neurontransmitter systems and incorporated into a computer-based cortical network model which implemented the physiology of 12 different membrane CNS targets. A biophysically realistic, multi-compartment model of 80 pyramidal cells and 40 interneurons was further calibrated usingdata reported for working memory tasks in healthyhumans and schizophrenia patients. Model output was the duration of the network firing activity in response to an external stimulus. Alzheimer’s disease (AD) pathology, in particular synapse and neuronal cell loss in addition to cholinergic deficits, was calibrated to align with the natural clinical disease progression. The model was used to provide insights into the effect of 5-HT4 activation on working memory and to prospectively simulate the response of PF- 04995274, a 5-HT4partial agonist, in a scopolamine-reversal trial in healthy human subjects. Results: The model output suggested a beneficial effect of 5-HT4
agonism on working memory. The model also projected no effect or an exacerbation of scopolamine impairment for low in- trinsic activity 5-HT4agonists, which was supported by the subsequent human trial outcome. The clinical prediction of the disease model strongly suggests that 5-HT4 agonists with high intrinsic activity may have a beneficial effect on cognition in AD patients.


Cite this paper

Nicholas, T. , Duvvuri, S. , Leurent, C. , Raunig, D. , Rapp, T. , Iredale, P. , Rowinski, C. , Carr, R. , Roberts, P. , Spiros, A. and Geerts, H. (2013) Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial. Advances in Alzheimer's Disease, 2, 83-98. doi: 10.4236/aad.2013.23012.

References

[1] Geerts, H. (2011) Modeling & Simulation as a tool for improving CNS drug research and development. Drug Development Research, 72, 66-73. doi:10.1002/ddr.20403
[2] van der Graaf, P.H. and Benson, N. (2011) Systems pharmacology: Bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharmaceutical Research, 28, 1460-1464. doi:10.1007/s11095-011-0467-9
[3] Alzheimer’s Association (2007) Every 72 seconds some- one in America Develops Alzheimer’s: Alzheimer’s disease facts and figures 2007.
[4] Braak, H. and Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica ogica, 82, 239-259. doi:10.1007/BF00308809
[5] Braak, H., Braak, E. and Bohl, J. (1993) Staging of Alzheimer-related cortical destruction. European Neurology, 33, 403-408. doi:10.1159/000116984
[6] Shin, R.W., Iwaki, T., Kitamoto, T., Sato, Y. and Tateishi, J. (1992) Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer’s disease. Demonstration using the hydrated autoclaving method. American Journal of Pathology, 140, 937-945.
[7] Thal, D.R., Griffin, S.T., de Vos, R.A. and Ghebremedhin, E. (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathologica, 115, 599-609. doi:10.1007/s00401-008-0366-2
[8] Braak, H., Tredici, K., Schultz, C. and Braak, E. (2000) Vulnerability of select neuronal types to Alzheimer’s disease. Annals of the New York Academy of Sciences, 924, 53-61. doi:10.1111/j.1749-6632.2000.tb05560.x
[9] Maher-Edwards, G., G., Dixon, R., Hunter, J., Gold, M., Hopton, G., Jacobs, G., Hunter, J. and Williams, P. (2011) SB-742457 and the donepezil and Alzheimer’s disease: A randomized, placebo-controlled study. International Journal of Geriatric Psychiatry, 26, 536-544. doi:10.1002/gps.2562
[10] Maher-Edwards, G., Zvartau-Hind, M., Hunter, A.J., Gold, M., Hopton, G., Jacobs, G., Davy, M. and Williams, P. (2010) Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s dis- ease. Current Alzheimer Research, 7, 374-385. doi:10.2174/156720510791383831
[11] Cirrito, J., Disabato, B.M. and Restivo, J. (2011) Serotonin signaling is associated with lower amyloid beta levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences, 108, 14968-14973. doi:10.1073/pnas.1107411108
[12] Consolo, S., Arnaboldi, S., Giorgi, S., Russi, G. and Ladinsky, H. (1994) 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. NeuroReport, 5, pp. 1230-1232. doi:10.1097/00001756-199406020-00018
[13] Eglen, R.M., Wong, E., Dumuis, A. and Bockaert, J. (1995) Central 5-HT4 receptors. Trends in Pharmacological Sciences, 16, pp. 391-398. doi:10.1016/S0165-6147(00)89081-1
[14] Kahana, M.J. (2006) The cognitive correlates of human brain oscillations. The Journal of Neuroscience, 26, pp. 1669-1672. doi:10.1523/JNEUROSCI.3737-05c.2006
[15] Megerian, J.T. (2009) Results of a phase 2A study of a novel 5HT4 agonist for the treatment of Alzheimer’s disease. American Society for Experimental Neuro Thera- peutics Annual Meeting, Arlington, 6 March 2009.
[16] Robert, S.J. and Lezoualc’h, F. (2008) Distinct functional effects of human 5-HT4 receptor isoforms on beta-amyloid secretion. Neurodegenerative Diseases, 5, pp. 163- 165. doi:10.1159/000113691
[17] Shen, F., Smith, J., Chang, R., Bourdet, D.L., Tsuruda, P., Obedencio, P. and Beattie, D.T. (2011) 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology, 61, pp. 69-79. doi:10.1016/j.neuropharm.2011.02.026
[18] Lezoualc’h, F. and Robert, S.J. (2003) The serotonin 5-HT4 receptor and the amyloid precursor protein processing. Experimental Gerontology, 38, 159-166. doi:10.1016/S0531-5565(02)00157-2
[19] Reynolds, G.P., Mason, S.L., Meldrum, A., De Keczer, S., Parties, H., Eglen, R.M. and Wong, E.H.F. (1995) 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: Distribution, pharmacology and effects of neurodegenerative diseases. British Journal of Pharmacology, 114, 993-998. doi:10.1111/j.1476-5381.1995.tb13303.x
[20] Vilaro, M.T., Cortes, R., Gerald, C., Branchek, T., Palacios, J.M. and Men-god, G. (1996) Localization of 5-HT4 receptor mRNA in rat brain by in situ hybridization histochemistry. Molecular Brain Research, 43, 356-360. doi:10.1016/S0169-328X(96)00248-3
[21] Geerts, H. (2011) Modeling & Simulation as a tool for improving CNS Drug Research and Development. Drug Development Research, 72, 66-73. doi:10.1002/ddr.20403
[22] Geerts, H., Spios, A. and Roberts, P. (2012) Has the time come for Quantitative Systems Pharmacology on CNS R&D. CPT: Pharmacometrics and Systems Pharmacology, 1, e16. doi:10.1038/psp.2012.17
[23] Povysheva, N.V., Zaitsev, A.V., Rotaru, D.C., Gonzalez-Burgos, G., Lewis, D.A. and Krimer, L.S. (2008) Parvalbumin-positive basket interneurons in monkey and rat prefrontal cortex. Journal of Neurophysiology, 100, pp. 2348-2360. doi:10.1152/jn.90396.2008
[24] Zaitsev, A.V., Povysheva, N., Gonzalez-Burgos, G., Rotaru, A.V., Fish, K.N., Krimer, L.S. and Lewis, D.A. (2009) Interneuron diversity in layers 2-3 of monkey prefrontal cortex. Cerebral Cortex, 19, 1597-1615. doi:10.1093/cercor/bhn198
[25] Hashimoto, T., et al., (2009) Protracted developmental trajectories of GABAA receptor alpha1 and alpha2 subunit expression in primate prefrontal cortex. Biological Psychiatry, 65, 1015-1023. doi:10.1016/j.biopsych.2009.01.004
[26] Drachman, D.A. and Leavitt, J. (1974) Human memory and the cholinergic system. A relationship to aging? Archives of Neurology, 30, 113-121. doi:10.1001/archneur.1974.00490320001001
[27] Rusted, J.M. and Warburton, D.M. (1988) The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology, 96, 145-152. doi:10.1007/BF00177553
[28] Ebert, U., Siepmann, M., Oertel, R., Wesnes, K.A. and Kirch, W. (1998) Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. Journal of Clinical Pharmacology, 38, 720-726. doi:10.1002/j.1552-4604.1998.tb04812.x
[29] Fredrickson, A., Snyder, P.J., Cromer, J., Thomas, E., Lewis, M. and Maruff, P. (2008) The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: An example with scopolamine. Human Psychopharmacology, 23, 425-436. doi:10.1002/hup.942
[30] Liem-Moolenaar, M., et al. (2010) The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. Journal of Psychopharmacology, 24, 1671-1679. doi:10.1177/0269881109106942
[31] Liem-Moolenaar, M., et al., (2011) Pharmacokinetic- pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. British Journal of Clinical Pharmacology, 71, 886-898. doi:10.1111/j.1365-2125.2011.03936.x
[32] Molchan, S.E., et al. (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Research Reviews, 17, pp. 215-226. doi:10.1016/0165-0173(92)90017-G
[33] Patat, A., Klein, M.J., Surjus, A., Hucher, M. and Granier, J. (1991) RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers. European Journal of Clinical Pharmacology, 41, 225-231. doi:10.1007/BF00315434
[34] Snyder, P.J., Bednar, M., Cromer, J.R. and Maruff, P. (2005) Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 1, 126-135. doi:10.1016/j.jalz.2005.09.004
[35] Thomas, E., et al. (2008) Specific impairments in visuospatial working and short-term memory following lowdose scopolamine challenge in healthy older adults. Neuropsychologia, 46, 2476-2484. doi:10.1016/j.neuropsychologia.2008.04.010
[36] Vitiello, B., et al. (1997) Cognitive and behavioral effects of cholinergic, dopaminergic, and seotonergic blockade in humans. Neuropsy-chopharmacology, 16, 15-24. doi:10.1016/S0893-133X(96)00134-0
[37] Roof, R., Sawant, A., Zaleska, M. and Iredale, P. (2011) Assessment of PF-04995274 in scopolamine disrupted Morris water maze compared to and in combination with donepezil. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 7, s772. doi:10.1016/j.jalz.2011.05.2219
[38] Geerts, H. (2012) alpha7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer’s disease. Expert Opinion on Investigational Drugs, 21, 59-65. doi:10.1517/13543784.2012.633510
[39] Roberts, P.D., Spiros, A. and Geerts, H. (2012) Simulations of symptomatic treat-ments for Alzheimer’s disease: Computational analysis of pathology and mechanisms of drug action. Alzheimer’s Research & Therapy, 4, 50. doi:10.1186/alzrt153
[40] Spiros, A., Carr, R. and Geerts, H. (2010) Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatric Disease and Treatment, 6, 589-603. doi:10.2147/NDT.S12460
[41] Spiros, A. and Geerts, H. (2012) A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development. Journal of Experimental Pharmacology, 4, 53-61. doi:10.2147/JEP.S30808
[42] Montague, P.R., et al. (2004) Dynamic gain control of dopamine delivery in freely moving animals. The Journal of Neuroscience, 24, 1754-1759. doi:10.1523/JNEUROSCI.4279-03.2004
[43] Ogren, S.O., et al. (2008) The role of 5-HT1A receptors in learning and memory. Behavioural Brain Research, 195, 54-77. doi:10.1016/j.bbr.2008.02.023
[44] John, C.E., Budygin, E.A., Mateo, Y. and Jones, S.R. (2006) Neurochemical characterization of the release and uptake of dopamine in ventral tegmental area and serotonin in substantia nigra of the mouse. Journal of Neurochemistry, 96, 267-282.
[45] Pendyam, S., Mohan, A., Kalivas, P.W. and Nair, S.S. (2009) Computational model of extracellular glutamate in the nucleus accumbens incorporates neuroadaptations by chronic cocaine. Neuroscience, 158, 1266-1276. doi:10.1016/j.neuroscience.2008.11.014
[46] Howes, O.D., Allan, V., McGuire, P., Stokes, P. and Kapur, S. (2009) Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Current Pharmaceutical Design, 15, 2550-2259. doi:10.2174/138161209788957528
[47] Durstewitz, D., Sea-mans, J.K. and Sejnowski, T.J. (2000) Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. Journal of Neurophysiology, 83, 1733-1750.
[48] DeFelipe, J. (2002) Cortical interneurons: From Cajal to 2001. Progress in Brain Research, 136, 215-238. doi:10.1016/S0079-6123(02)36019-9
[49] Sidiropoulou, K., et al. (2009) Dopamine modulates an mGluR5-mediated depolarization underlying prefrontal persistent activity. Nature Neuroscience, 12, 190-199.
[50] Isaacson, J.S. and Scanziani, M. (2011) How inhibition shapes cortical activity. Neuron, 72, 231-243. doi:10.1016/j.neuron.2011.09.027
[51] Bijak, M., Zahorodna, A. and Tokarski, K. (2001) Opposite effects of antidepressants and corticosterone on the sensitivity of hippocampal CA1 neurons to 5-HT1A and 5-HT4 receptor activation. Naunyn-Schmiedeberg’s Archives of Pharmacology, 363, 491-498. doi:10.1007/s002100000389
[52] Bockaert, J., Claeysen, S., Compan, V. and Dumuis, A. (2004) 5-HT4 receptors. Current Drug Target-CNS & Neurological Disorders, 3, 39-51. doi:10.2174/1568007043482615
[53] Ansanay, H., Dumuis, A., Sebben, M., Bockaert, J. and Fagni, L. (1995) cAMP-dependent, long-lasting inhibittion of a K+ current in mammalian neurons. Proceedings of the National Academy of Sciences of the United States of America, 92, 6635-6639. doi:10.1073/pnas.92.14.6635
[54] Torres, G.E., Arfken, C.L. and Andrade, R. (1996) 5-Hydroxytryptamine4 receptors reduce afterhyperpolarization in hippocampus by inhibiting calcium-induced calcium release. Molecular Pharmacology, 50, 1316-1322.
[55] Cai, X., Flores-Hernandez, J., Feng. J. and Yan, Z. (2002) Activity-dependent bidirectional regulation of GABAA receptor channels by the 5-HT4 receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. The Journal of Physiology, 540, 743-759. doi:10.1113/jphysiol.2001.013391
[56] Lucas, G., et al. (2005) Frontocortical 5-HT4 receptors exert positive feedback on ser-otonergic activity: Viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biological Psychiatry, 57, 918-925. doi:10.1016/j.biopsych.2004.12.023
[57] Lucas, G. and Debonnel, G. (2002) 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. European Journal of Neuroscience, 16, 817-822. doi:10.1046/j.1460-9568.2002.02150.x
[58] Gulledge, A.T. and Stuart, G.J. (2005) Cholinergic inhibittion of neocortical pyramidal neurons. The Journal of Neuroscience, 25, 10308-10320. doi:10.1523/JNEUROSCI.2697-05.2005
[59] Timofeeva, O.A. and Levin, E.D. (2011) Glutamate and nicotinic receptor interactions in working memory: Importance for the cognitive impairment of schizophrenia. Neuroscience, 195, 21-36. doi:10.1016/j.neuroscience.2011.08.038
[60] Zappettini, S., Grilli, M., Salamone, A., Fedele, E. and Marchi, M. (2010) Presynaptic nicotinic receptors evoke endogenous glutamate and aspartate release from hippocampal synaptosomes by way of distinct coupling mechanisms. British Journal of Pharmacology, 161, 1161- 1171. doi:10.1111/j.1476-5381.2010.00958.x
[61] Parikh, V., Ji, J., Decker, M.W. and Sarter, M. (2010) Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. The Journal of Neuroscience, 30, 3518-3530. doi:10.1523/JNEUROSCI.5712-09.2010
[62] Alkondon, M., Pereira, E., Eisenberg, H. and Albuquerque, E. (2000) Nicotinic receptor activation in human cerebral cortical interneurons: A mechanism for inhibition and disinhibition of neuronal net-works. The Journal of Neuroscience, 20, 66-75.
[63] Brodney, M., et al. (2012) Identification of multiple 5-HT4 partial agonist clinical candidates for the treatment of Alzheimer’s disease. Journal of Medicinal Chemistry, 55, 9240-9254. doi:10.1021/jm300953p
[64] Collie, A., et al. (2007) Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study. Contemporary Clinical Trials, 28, 391-400. doi:10.1016/j.cct.2006.10.010
[65] Woodruff-Pak, D.S. and Gould, T.J. (2002) Neuronal nicotinic acetylcholine receptors: Involvement in Alzheimer’s disease and schizophrenia. Behavioral and Cognitive Neuroscience Reviews, 1, 5-20. doi:10.1177/1534582302001001002
[66] Geerts, H., Finkel, L., Carr, R. and Spiros, A. (2002) Nicotinic receptor modulation: Advantages for successful Alzheimer’s disease therapy. Journal of Neural Transmission Supplementum, 62, 203-216.
[67] Kadir, A., et al. (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiology of Aging, 29, 1204-1217. doi:10.1016/j.neurobiolaging.2007.02.020
[68] Tariot, P.N., et al. (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54, 2269-2276. doi:10.1212/WNL.54.12.2269
[69] Raskind, M.A., Peskind, E., Truyen, L., Kershaw, P. and Damaraju, C. (2004) The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial. Archives of Neurology, 61, 252-256. doi:10.1001/archneur.61.2.252
[70] Slutsky, I., et al. (2003) Use of knockout mice reveals involvement of M2-muscarinic receptors in control of the kinetics of acetylcholine release. Journal of Neurophysiology, 89, 1954-1967. doi:10.1152/jn.00668.2002
[71] Bolden, C., Cusack, B. and Richelson, E. (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. Journal of Pharmacology and Experimental Therapeutics, 260, 576-580.
[72] Carson, R.E., et al. (1998) Muscarinic cholinergic recaptor measurements with [18F]FP-TZTP: Control and competition studies. Journal of Cerebral Blood Flow & Metabolism, 18, 1130-1142. doi:10.1097/00004647-199810000-00010
[73] Matsumoto, M., et al. (2001) Evidence for involvement of central 5-HT4 receptors in cholinergic function associated with cognitive processes: Behavioral, electrophysiological, and neurochemical studies. Journal of Pharmacology and Experimental Therapeutics, 296, 676-682.
[74] de Vin, F., De Maeyer, J.H. and Lefebvre, R.A. (2011) Invitro acetylcholine release is not a straightforward model to study hippocampal 5-HT4 receptors. Neuroreport, 22, 892-896. doi:10.1097/WNR.0b013e32834c7fd4
[75] Sheiner, L.B. (1997) Learning versus confirming in clinical drug development. Clinical Pharmacology & Therapeutics, 61, 275-291.
[76] Perry, M.J., Lawson, S.N. and Robertson, J. (1991) Neurofilament immunoreactivity in populations of rat primary afferent neurons: A quantitative study of phosphorylated and non-phosphorylated subunits. Journal of Neurocytology, 20, 746-758. doi:10.1007/BF01187848
[77] Iwakiri, M., et al. (2009) An immunohistochemical study of GABAA receptor gamma subunits in Alzheimer’s disease hippocampus: Relationship to neurofibrillary tangle progression. Neuropathology, 29, 263-269. doi:10.1111/j.1440-1789.2008.00978.x
[78] Rissman, R.A., et al. (2003) Biochemical analysis of GABAA receptor subunits alpha 1, alpha 5, beta 1, beta 2 in the hippocampus of patients with Alzheimer’s disease neuropathology. Neuroscience, 120, 695-704. doi:10.1016/S0306-4522(03)00030-7
[79] Mizukami, K., Grayson, D., Ikonomovic, M., Sheffield, R. and Armstrong, D. (1998) GABAA receptor beta 2 and beta 3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimer-related neuropathology. Molecular Brain Research, 56, 268-272. doi:10.1016/S0169-328X(97)00347-1
[80] Koliatsos, V.E., et al. (2006) Early involvement of small inhibitory cortical inter-neurons in Alzheimer’s disease. Acta Neuropathologica ogica, 112, 147-162. doi:10.1007/s00401-006-0068-6
[81] Seidl, R., Cairns, N., Singewald, N., Kaehler, S. and Lubec, G. (2001) Differences between GABA levels in Alzheimer’s disease and Down syndrome with Alzheimer-like neuropathology. Naunyn-Schmiedeberg’s Archives of Pharmacology, 363, 139-145. doi:10.1007/s002100000346
[82] Puig, M.V., Santana, N., Celada, P., Mengod, G. and Artigas, F. (2004) In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cerebral Cortex, 14, 1365-1375. doi:10.1093/cercor/bhh097
[83] Grider, J.R. (2006) Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod. American Journal of Physiology-Gastrointestinal and Liver Physiology, 290, G319-G327. doi:10.1152/ajpgi.00326.2005
[84] Mialet, J., Fischmeister, R. and Lezoualc’h, F. (2003) Characterization of human 5-HT4(d) receptor desensitization in CHO cells. British Journal of Pharmacology, 138, 445-452. doi:10.1038/sj.bjp.0705061
[85] Lefebvre, H., et al. (1998) Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocrine Research, 24, 749-752. doi:10.3109/07435809809032681
[86] Ouchi, Y., et al. (2009) Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. The Journal of Nuclear Medicine, 50, 1260-1266. doi:10.2967/jnumed.109.063008
[87] Hendricksen, M., Thomas, A., Ferrier, I.N., Ince, P. and O’Brien, J. (2004) Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer’s disease with and without depression. American Journal of Psychiatry, 161, 1096-1102. doi:10.1176/appi.ajp.161.6.1096

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.